Vimarsana
Biggest News Aggregation in the World

Page 8 - Alpine Immune Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alpine Immune Sciences Today - Breaking & Trending Today

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN - Vimarsana News

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Alpine Immune Sciences, Inc. to Vertex...

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders -April 10, 2024 at 08:09 pm EDT - Vimarsana News

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders -April 10, 2024 at 08:09 pm EDT

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine...

Vertex acquires Alpine for $4.9 billion in cash - Vimarsana News

Vertex acquires Alpine for $4.9 billion in cash

The transaction is expected to close during the second quarter of 2024

Source: qz.com
These Stocks Are Moving the Most Today - Vimarsana News

These Stocks Are Moving the Most Today

Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Costco boosts its quarterly dividend, and Constellation Brands,…

Source: biztoc.com
Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal - Vimarsana News

Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal

The deal values each share of Alpine at $65